12th Mar 2018 07:56
Based on current predictions, the FTSE 100-listed biopharmaceutical products company now expects analysis of overall survival to be released in the second half of 2018, previously expected in the first half of the year.
The trial is for Imfinzi as monotherapy and combined with antibody tremelimumab, against platinum-based standard of care chemotherapy in untreated patients with metastatic 1st line non-small cell lung cancer.
Imfinzi, known also as durvalumab, is a human monoclonal antibody which blocks the interaction of PD-L1 with PD-1 and CD80, which counters the tumour's immune system evading tactics and releases the inhibition of immune responses.
Related Shares:
Astrazeneca